KDR

(redirected from VEGFR-2)
Also found in: Acronyms.

KDR

A gene on chromosome 4q11-q12 that encodes a vascular endothelial growth factor receptor known as kinase insert domain receptor, which is a type-III receptor tyrosine kinase. KDR is the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting.

Molecular pathology
KDR mutations have been linked to infantile capillary haemangiomas.
Mentioned in ?
References in periodicals archive ?
Ambati, "Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors," Annals of the New York Academy of Sciences, vol.
Herrick, "The differential expression of VEGF, VEGFR-2, and GLUT1 proteins in disease subtypes of systemic sclerosis," Human Pathology, vol.
In dogs VEGFR-2 was detected in a few canine tumors including cutaneous SCC, simple mammary gland adenocarcinoma, fibrosarcoma [59, 60, 79], apocrine gland anal sac adenocarcinoma, and thyroid carcinoma [96].
unpublished data) suggest that VEGFR-1, but not VEGFR-2, is expressed significantly in nonmalignant cells and closely linked with CD68 infiltration "a M2 macrophage marker," suggesting that it may have a greater role than VEGFR-2 in TME (Figure 3(a)).
who stated that, after the induction of colitis, the expression of both VEGF-A and VEGFR-2 was markedly enhanced, whereas no increase in the expression of VEGFR-1 was observed [18].
Vascular endothelial growth factor receptor 2 (VEGFR-2) functions to promote uterine decidual angiogenesis during early pregnancy in the mouse.
Functional early EPC is charactarised by three markers: CD133, CD34 and vascular endothelial growth factor receptor-2 (VEGFR-2) which is also called kinase insert domain receptor (KDR) or Flk-1.
VEGF interacts with 2 receptor tyrosine kinases, VEGFR-1 and VEGFR-2. Increased VEGF concentrations were found to correlate with a poor prognosis in cancer (3-8).
ImClone Systems Incorporated (NASDAQ: IMCL) and UCB have entered into a worldwide strategic partnership for the development and commercialization of CDP-791, a novel, investigational antibody targeting the vascular endothelial growth factor receptor-2 (VEGFR-2) that is currently being developed by UCB.
These angiogenic growth factors include the vascular endothelial growth factor family (VEGF) and its receptors (VEGFR-1 and VEGFR-2), the angiopoietins (Ang-1 and Ang-2) along with their common receptor Tie-2.
These SPCs are similar to EPCs as they express VEGFR-2 but not haematopoietic markers, such as CD45; however, unlike EPCs, SPCs do not express CD31 and CD146.
VEGF-A binds to and activates the tyrosine kinase receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) [2].